Daiichi Sankyo Valuation Multiples

Daiichi Sankyo Overview

About Daiichi Sankyo

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Founded

2005

HQ

Employees

19.8K

Website

daiichisankyo.co.jp

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $13B

EBITDA: $3B

EV

$30B

Valuation Multiples

Multiples.vc

Start free trial

Daiichi Sankyo Financials

Daiichi Sankyo reported last 12-month revenue of $13B and EBITDA of $3B.

In the same LTM period, Daiichi Sankyo generated $11B in gross profit, $3B in EBITDA, and $2B in net income.

Daiichi Sankyo P&L

In the most recent fiscal year, Daiichi Sankyo reported revenue of $13B and EBITDA of $3B.

Daiichi Sankyo expects next 12-month revenue of XXX and NTM EBITDA of XXX

Daiichi Sankyo Stock Performance

Daiichi Sankyo has current market cap of $32B, and enterprise value of $30B.

Daiichi Sankyo's stock price is $17.69.

Daiichi Sankyo Valuation Multiples

Daiichi Sankyo trades at 2.2x EV/Revenue multiple, and 11.2x EV/EBITDA.

Daiichi Sankyo Financial Valuation Multiples

As of April 10, 2026, Daiichi Sankyo has market cap of $32B and EV of $30B.

Equity research analysts estimate Daiichi Sankyo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Daiichi Sankyo has a P/E ratio of 16.7x.

Daiichi Sankyo Margins & Growth Rates

Daiichi Sankyo's revenue in the last 12 month grew by 11%.

Daiichi Sankyo's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.4M for the same period.

Daiichi Sankyo's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Daiichi Sankyo's rule of X is 49% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Daiichi Sankyo Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Daiichi Sankyo M&A Activity

Daiichi Sankyo acquired XXX companies to date.

Last acquisition by Daiichi Sankyo was on XXXXXXXX, XXXXX. Daiichi Sankyo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Daiichi Sankyo Investment Activity

Daiichi Sankyo invested in XXX companies to date.

Daiichi Sankyo made its latest investment on XXXXXXXX, XXXXX. Daiichi Sankyo invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).